tRNA-derived fragments-antisense oligonucleotides-exosomes

Phase 2Small molecule

AAffiliated Hospital of Nantong University

tRNA-derived fragments-antisense oligonucleotides-exosomes is one of 2 small molecule programs targeting Ocular Surface Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular Surface DiseaseNot yet recruiting

Ocular Surface DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Ocular Surface Disease

#DrugCompanyPhaseTrials

Exosomes

GGuangzhou Bio-gene Technology Co., Ltd

Phase 2

1 2

tRNA-derived fragments-antisense oligonucleotides-exosomes

AAffiliated Hospital of Nantong University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Not yet recruiting

Ocular Surface Disease

NCT07382453

Clinical

Trials by Indication[1]

Ocular Surface Disease1 trial

Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases

Not yet recruiting·—·Phase 2·NCT07382453·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for tRNA-derived fragments-antisense oligonucleotides-exosomes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tRNA-derived fragments-antisense oligonucleotides-exosomes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tRNA-derived fragments-antisense oligonucleotides-exosomes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Affiliated Hospital of Nantong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAffiliated Hospital of Nantong University

tRNA-derived fragments-antisense oligonucleotides-exosomes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Ocular Surface Disease1 trial

References

Drug Info

Quick Facts

Related News